Literature DB >> 34852649

Open-Source Algorithm to Calculate Mean Amplitude of Glycemic Excursions Using Short and Long Moving Averages.

Nathaniel J Fernandes1, Nhan Nguyen1, Elizabeth Chun2, Naresh M Punjabi3, Irina Gaynanova4.   

Abstract

Entities:  

Keywords:  MAGE; continuous glucose monitoring; glucose metrics; glucose variability; type 1 diabetes; type 2 diabetes

Mesh：

Substances：

Year:  2021        PMID： 34852649      PMCID： PMC8861796          DOI： 10.1177/19322968211061165

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN： 1932-2968


× No keyword cloud information.
  4 in total

1.  Mean amplitude of glycemic excursions, a measure of diabetic instability.

Authors:  F J Service; G D Molnar; J W Rosevear; E Ackerman; L C Gatewood; W F Taylor
Journal:  Diabetes       Date:  1970-09       Impact factor: 9.461

2.  Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.

Authors:  Nathan R Hill; Nick S Oliver; Pratik Choudhary; Jonathan C Levy; Peter Hindmarsh; David R Matthews
Journal:  Diabetes Technol Ther       Date:  2011-06-29       Impact factor: 6.118

3.  cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data.

Authors:  Tim Vigers; Christine L Chan; Janet Snell-Bergeon; Petter Bjornstad; Philip S Zeitler; Gregory Forlenza; Laura Pyle
Journal:  PLoS One       Date:  2019-10-11       Impact factor: 3.240

4.  Interpreting blood GLUcose data with R package iglu.

Authors:  Steven Broll; Jacek Urbanek; David Buchanan; Elizabeth Chun; John Muschelli; Naresh M Punjabi; Irina Gaynanova
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240
  4 in total
  2 in total

1.  Large-Scale Data Analysis for Glucose Variability Outcomes with Open-Source Automated Insulin Delivery Systems.

Authors:  Arsalan Shahid; Dana M Lewis
Journal:  Nutrients       Date:  2022-05-02       Impact factor: 6.706

2.  Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass.

Authors:  Antonio Ferreira; Ahmed Fahiem Abdelsalam Emara; David Herzig; Andreas Melmer; Andreas P Vogt; Christos T Nakas; Andrea Facchinetti; Chiara Dalla Man; Lia Bally
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.